OBM Neurobiology is an international peer-reviewed Open Access journal published quarterly online by LIDSEN Publishing Inc. By design, the scope of OBM Neurobiology is broad, so as to reflect the multidisciplinary nature of the field of Neurobiology that interfaces biology with the fundamental and clinical neurosciences. As such, OBM Neurobiology embraces rigorous multidisciplinary investigations into the form and function of neurons and glia that make up the nervous system, either individually or in ensemble, in health or disease. OBM Neurobiology welcomes original contributions that employ a combination of molecular, cellular, systems and behavioral approaches to report novel neuroanatomical, neuropharmacological, neurophysiological and neurobehavioral findings related to the following aspects of the nervous system: Signal Transduction and Neurotransmission; Neural Circuits and Systems Neurobiology; Nervous System Development and Aging; Neurobiology of Nervous System Diseases (e.g., Developmental Brain Disorders; Neurodegenerative Disorders).
OBM Neurobiology publishes research articles, technical reports and invited topical reviews. Although the OBM Neurobiology Editorial Board encourages authors to be succinct, there is no restriction on the length of the papers. Authors should present their results in as much detail as possible, as reviewers are encouraged to emphasize scientific rigor and reproducibility.
Archiving: full-text archived in CLOCKSS.
Publication Speed (median values for papers published in 2022): Submission to First Decision: 6 weeks; Submission to Acceptance: 14 weeks; Acceptance to Publication: 8 days (1-2 days of FREE language polishing included)
Biochemical Markers in Neurodegenerative Diseases
Submission Deadline: March 15, 2024 (Open) Submit Now
Maria Morello, PhD, Adjunct Professor (Biography)
Clinical Biochemistry and Molecular Biology, Department of Experimental Medicine Tor Vergata University, Rome, Italy
Research Interests: the study of biochemical markers in neurodegenerative diseases as well as cytokines and vitamins in autoimmune diseases; the evaluation of cytokine and inflammatory markers in Covid
About This Topic
Several neurodegenerative diseases (such as: Alzheimer's, Parkinson's, Huntington's, Amyotrophic Lateral Sclerosis, frontotemporal dementia and Lewy body dementia), are characterized by an irreversible, as well as progressive loss of neuronal cells of the central nervous system. The pathological manifestation of neurodegeneration depends on the brain area affected by the neuronal loss and on the type of neurons involved. Currently the measurement of some biomarkers of neurodegenerative diseases (known to date, i.e., molecules and proteins) is supportive to the clinician. However, the quantification of these biomarkers is limited: i) some of those need to be collected using invasive techniques ii) other protein biomarkers can only be identified in post-mortem tissues, but above all iii) all biomarkers known show limited specificity and sensitivity, (especially in the early stages of illness). In addition, when the brain damage is not yet irreversible, the identification of specific and new biomarkers of neurodegeneration represents a powerful tool to obtain a correct diagnosis. Such biomarkers could also be used as therapeutic target for precise pharmacological treatments.
Potential topics include: i) the measurement of classical and new neurodegenerative biomarkers (specific proteins, inflammatory molecules, and other such as miRNA) in central nervous system, peripheral tissues and biological fluids (such as urine, blood, cerebrospinal fluid, saliva or other tissues); ii) the description of innovative molecular and biochemical techniques (Cryogenic electron Microscopy, Mass Spectrometry and others) that allow the isolation, identification and characterization of biomarkers; and in conclusion iii) the analysis of these new approaches in combination with radiological imaging and clinical signs linked to the severity of the disease, permits to establish an early and a non-invasive precise diagnosis and optimize potential treatment strategies.
Manuscript Submission Information
Manuscripts should be submitted online at http://www.lidsen.com/Passport/Index/login by registering and logging in to this website. Once registered and activated, please click here to go to the submission form. A guide for authors and other relevant information for submission of manuscripts is available on Instructions for Authors.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are highly invited. For planned papers, a tentative title and short abstract (about 100 words) can be sent to the Editorial Office (firstname.lastname@example.org) for record. Welcome your submission!
To prevent robots and page crawlers from submitting fraudulent forms, complete verification to prove that you are a human.